AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy

AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to move the needle in the chronic skin disease hidradenitis suppurativa, leading the biotech to stop work on one indication and plan to out-license the asset.